Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market

www.MarketResearchReports.com

Non-Small Cell Lung Cancer Market to

2020 - New Therapies to

Enhance Treatment Segmentation and Drive Growth in an

Increasingly Competitive Market

Category : Pharma & Healthcare

All logos and Images mentioned on this slide belong to their respective owners.

http://www.marketresearchreports.com/


Introduction to Report

Launch Date: July 31, 2014

Number of Pages: 143

Geography Coverage: Global

Available Format: PDF

Price For Single User License: USD 3,500

Price For Site User License: USD 7,000

Price For Global User License: USD 10,500

Delivery Time: Within 24 Hours (During Working Days)



About the Report

"Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market" report focuses on the increasing differentiation between the three main NSCLC subtypes: squamous cell, adenocarcinoma, and large cell carcinoma.

The report assesses the current NSCLC market and predicts market trends to 2020, analyzing key drivers and barriers.



Research Finding

The value of the Non-Small Cell Lung Cancer (NSCLC) market is expected to increase significantly over the forecast period across the leading eight developed nations, from $5.1 billion in 2013 to $7.9 billion in 2020.

This equates to a Compound Annual Growth Rate (CAGR) of 6.6%. Growth will be driven by novel therapies entering the squamous cell carcinoma market segment, which is currently lacking effective treatment, unlike the non-squamous market segment.

New second-line therapies include immunostimulants such as ramucirumab and nivolumab, which have shown clinical benefits, but which will face difficulties due to the increasingly crowded second-line setting. Currently, pharmaceutical treatment is limited to late-stage patients.



Research Finding Continues…

Over the forecast period to 2020, several new additions to the NSCLC treatment paradigm will transform the treatment landscape. Many of these will be monoclonal Antibodies (mAbs), which instigate an immune response to the tumor rather than directly affecting cancer cells.

Squamous cell histology accounts for approximately 30% of the NSCLC population, and pipeline products, such as Yervoy (ipilimumab) in the first-line treatment and nivolumab in the second-line, will add greater diversity to the treatment algorithm, with both having shown clinical benefits in early-stage trials.



Scope A disease introduction, which defines the disease and

looks at symptoms, diagnosis and treatment

Analysis of the NSCLC marketed landscape, including a comparison of the efficacy and safety of the most prominent brands, as well as the unmet needs of NSCLC treatment

Detailed analysis of the NSCLC pipeline, covering among other parameters, drug distribution by Phase, molecule type and mechanism of action. The NSCLC clinical trial landscape is analyzed with particular emphasis on failure rates across different trial Phases, as well as the trends in clinical trial size, duration and primary endpoint.

This section also includes profiles and single product forecasts for the most promising pipeline drugs.



Scope Continues… An epidemiological forecast of the major NSCLC

markets, in which projected values include total and treated populations

An in-depth forecasting model for the NSCLC market, which considers the current marketed therapies in addition to the potential entry of new products to the market. The model comprises a projected outcome with high and low variance results depending on the potential performance of pipeline therapies.

Analysis of strategic consolidations within the NSCLC indication, including co-development and licensing agreements

An overview of the drivers of and barriers to the NSCLC market



Report Coverage

1. Introduction2. Marketed Products3. NSCLC Pipeline4. Market Forecast5. Strategic Consolidations6. Appendix

For more details regarding Report coverage see the last slide

All logos and Images mentioned on this slide belong to their respective owners.



Custom Research: Are you an industry professional, entrepreneur,

venture capitalist, investors and organization, then let us know your specific research requirements. Our goal is to cater to your requirements be it for a custom market research project, syndicated research report on a specific market or industry sector, newsletter creation, case study development or anything else related to marketing research.

For Any Customization Related query Visit IdeaCenter @http://www.marketresearchreports.com/idea-center

http://www.marketresearchreports.com/idea-center



How To Buy This Report?

Visit following URL to see Table of Content and purchase this publication:

http://mrr.cm/Z7K

About Market Research Reports, Inc.Market Research Reports provides a customized set of reports from reputed Publishers, built on the intelligence available within organizations and leverages on our motto of “Intelligence Redefined”.

Contact : Amitava SenEmail : [email protected]: +1 302-703-7787 (USA) +91-8762746600 (India)

http://mrr.cm/Z7K

http://mrr.cm/Z7K

mailto:[email protected]
